No Data
No Data
MaxCyte Sees Shift in BlackRock's Shareholding
This MaxCyte Insider Increased Their Holding In The Last Year
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
BTIG Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $8
MaxCyte Weighs Delisting From AIM to Prioritize Nasdaq: Potential Benefits and Risks Ahead
Stifel Maintains MaxCyte(MXCT.US) With Buy Rating, Maintains Target Price $11